Evercore ISI raised the firm’s price target on Twist Bioscience (TWST) to $52 from $42 and keeps an Outperform rating on the shares. Driven by NGS normalization and AI-driven drug discovery, Twist Bioscience is “set for solid growth into FY26,” the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $50 from $39 at Barclays
- Twist Bioscience Earnings Call Highlights AI-Driven Growth
- Midday Fly By: Disney slips despite Q1 beat, Devon to combine with Coterra
- Twist Bioscience rises 12.5%
- Twist Bioscience: Solid Execution, Raised 2026 Outlook, and Discounted Valuation Support Buy Rating